Regulation & law · 20/12/2017Updated: 10/17/2026 · 1 min read

National Cancer Institute Considers Exclusive Patent License for Anti-CD30 CAR Cancer Treatment

The National Cancer Institute, part of the National Institutes of Health, Department of Health and Human Services, is evaluating a potential exclusive patent license agreement with Kite Pharma, Inc. to develop an anti-CD30 chimeric antigen receptor (CAR) for cancer treatment.